| Filed On | Filing |
|---|---|
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | S-8 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half... |
| 01 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
IN8bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows: |
| 01 Jun 2026 | 424B5 |
| 29 May 2026 | SCHEDULE 13D/A |
| 29 May 2026 |
Form 4: Fairbairn Emily, Director
Gave 724,637 shares as a gift |
| 19 May 2026 | EFFECT |
| 18 May 2026 | S-3/A |
| 15 May 2026 | CORRESP |
| 12 May 2026 |
Form 4: Ho William Tai-Wei, Director
Granted 154,500 Employee Stock Option (right to buy) |
| 12 May 2026 |
Form 4: Greenwood Luba, Director
Granted 22,000 Stock Option (right to buy) |
| 12 May 2026 |
Form 4: Lamb Lawrence, EVP and CSO
Granted 54,000 Employee Stock Option (right to buy) |
| 12 May 2026 |
Form 4: Fairbairn Emily, Director
Granted 22,000 Stock Option (right to buy) |
| 12 May 2026 |
Form 4: McCall Patrick, CHIEF FINANCIAL OFFICER
Granted 56,250 Employee Stock Option (right to buy) |
| 12 May 2026 |
Form 4: Rochlin Kate, President and COO
Granted 60,000 Employee Stock Option (right to buy) |
| 12 May 2026 |
Form 4: Epperly Corinne, Director
Granted 22,000 Stock Option (right to buy) |
Loading...